Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine

J Natl Cancer Inst. 1975 Jan;54(1):69-71. doi: 10.1093/jnci/54.1.69.

Abstract

In a randomized, controlled study of 80 patients with advanced colorectal carcinoma, the combination of 5-fluorouracil (5-FU), methyl-1, 3-cis(2-chlorethyl)-1-nitrosourea, and vincristine produced an overall degree to toxicity comparable to that of 5-FU used alone. At 10 weeks, a positive objective response rate of 43.5% was observed with the three-drug combination compared to 19.5% with 5-FU alone (P less than 0.5).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Cyclohexanes / adverse effects
  • Cyclohexanes / analogs & derivatives
  • Cyclohexanes / therapeutic use
  • Evaluation Studies as Topic
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Fluorouracil / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Nitrosourea Compounds / administration & dosage
  • Nitrosourea Compounds / adverse effects
  • Nitrosourea Compounds / therapeutic use*
  • Rectal Neoplasms / drug therapy*
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Vincristine / therapeutic use*

Substances

  • Antineoplastic Agents
  • Cyclohexanes
  • Nitrosourea Compounds
  • Vincristine
  • Fluorouracil